Patch Testing Note (Reading/Interpretation)

Date/Time of Reading: [Date and time of this reading / Unknown/Not recorded]

Reader: [Clinician name and role / Unknown/Not recorded]

Encounter Type: [Patch Test Reading/Interpretation]

Reference Episode: [Link or identifier to patch placement visit/episode]

Patch Test Context

[Patch test system/series used] (Briefly list series and materials tested: e.g., baseline series, supplemental series, patient products, occupational materials.)

• Placement (D0): [Date/time of application / Timing not available]
• Removal: [Date/time of removal]
• This reading: [D2 / D3 / D4 / D7 / Other]
• Additional readings planned: [Yes: specify timing / No]
• Validity considerations: [Recent topical/systemic corticosteroids / immunosuppressants / UV exposure / angry back/diffuse dermatitis / patch detachment / excessive sweating / none noted] (Include only if present; otherwise omit.)

(If placement timing is unavailable, explicitly note interpretation is limited.)

Interval History

(Include this section only if events since placement affect interpretation or management; otherwise omit entirely.)

• [Adherence issues] (e.g., patch detachment, patches got wet, applied products to back)
• [Symptoms at test sites] (e.g., pruritus, burning, pain, sleep disruption)
• [Flare of dermatitis elsewhere]
• [Current status of index dermatitis that prompted testing]

Patch Site Examination

• Overall back assessment: [Markings clear / faded], [Diffuse erythema present / absent], [Angry back pattern present / absent]
• Complications observed: [Vesiculation / erosions / secondary infection / significant edema / pigment change / none observed]
• Clinical photos: [Taken / Not taken]

Patch Test Results

(Repeat the following subsection for each reading documented today.)

[D2 / D3 / D4 / D7]: [Date/time] ([Hours since application])

Reading quality/concerns: [None / Partial detachment of patches / Diffuse background erythema / Markings unclear / Other]

Allergen Name	Concentration/Vehicle	Series/Source	Score (ICDRG)	Morphology Notes	Final Interpretation
[Allergen name]	[Concentration/vehicle]	[Series/source]	[− / ? / + / ++ / +++ / IR / NT]	[Morphology qualifiers] (Optional; use for equivocal or borderline reactions.)	[Positive/allergic / Irritant / Doubtful / Negative / Not tested]

(List all positive, doubtful, and irritant reactions individually. Summarize negatives as: "All other tested allergens negative at this reading." Explicitly list any allergens that could not be read as NT/uninterpretable; do not omit.)

Interpretation Summary

[Synthesis of findings across readings] (Summarize allergens with allergic sensitization vs irritant reactions. Note crescendo vs decrescendo patterns relevant to distinguishing allergic from irritant. If readings are incomplete or validity compromised, explicitly state limitations. If doubtful reactions are interpreted as clinically significant, document rationale including timing evolution, morphology, and exposure correlation.)

Clinical Relevance

(Required for each allergen interpreted as positive/allergic. Do not infer relevance from score alone; document exposure linkage and clinical correlation.)

[Allergen name]

• Relevance: [Current / Past / Unknown / Cross-reaction]
• Exposure rationale: [Suspected/confirmed sources and correlation with dermatitis distribution]
• Plan to clarify: [Product ingredient verification / Workplace SDS review / Use test (ROAT) / Expanded testing] (Include only if relevance uncertain.)

Assessment

• [Allergic contact dermatitis due to: list allergen(s)]
• [Irritant contact dermatitis] (Include if supported.)
• [Coexisting conditions] (e.g., atopic dermatitis, if relevant)
• [Occupational contact dermatitis considerations] (Include if applicable.)
• [Adverse reactions to testing] (e.g., severe vesiculation, secondary infection; include if present.)

Plan

Allergen Avoidance

(Repeat for each relevant allergen.)

• [Allergen name]: [Common sources and where found, including patient-specific products]
• Synonyms for label reading: [Key synonyms/alternate names]
• Cross-reactors: [List if counseled]
• Avoidance strategy: [Products to stop/replace, workplace modifications, PPE recommendations]
• Resources provided: [Allergen info sheets / Safe product lists / Database access / Personalized safe list]

Treatment

• [Topical anti-inflammatory therapy] (Specify potency, site, frequency, duration.)
• [Emollients/barrier care]
• [Anti-pruritic measures]
• [Treatment for secondary infection] (If present.)
• [Care instructions for severe patch site reactions]

Additional Workup

(Include only if applicable.)

• [Late reading planned: specify timing]
• [Repeat or expanded series testing]
• [Use test/ROAT for equivocal results]
• [Occupational investigation: workplace visit, SDS review, occupational medicine referral]
• [Photopatch testing if photoallergic contact dermatitis suspected]

Follow-up

• Return visit: [Timeframe, typically 6–8 weeks after initiating avoidance / sooner if severe]
• Return precautions: [Worsening dermatitis / Signs of infection / Severe blistering / Systemic symptoms]